Track the 티움바이오 stock price and the full directors' dealings record of the company, a listed equity based in South Korea. Shares trade on KR KR, under the oversight of DART (FSS). Operating in the Health Care sector, 티움바이오 has published 24 insider filings. Market capitalisation: €117.5bn. The latest transaction was filed on 24 June 2026 (Other). Among the most active insiders: 김훈택. All data is free.
24
Insider Decl.
0
Thresholds
·
3 ops.
Buy Volume
·
3 ops.
Sell Volume
22Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 23,231 of 26,293 companies
23.6
score / 100
Value
13
Quality
34
FCF yld-13%
Earn yld-15%
EV/EBITDA·
ROE-32%
Gross mgn41%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
티움바이오 is a company in the health and pharmaceutical sector, listed on the XKRX market. It focuses on developing innovative therapies and biopharmaceutical solutions.